Final safety findings from a randomized phase III trial of preoperative FU-based chemoradiation +/- weekly oxaliplatin as neoadjuvant therapy for patients with locally advanced rectal cancer: the STAR (Studio Terapia Adiuvante Retto)-01 randomized trial

Reviewer: Christine Hill, MD
The Abramson Cancer Center of the University of Pennsylvania
Ultima Vez Modificado: 7 de febrero del 2009

Translation for this article does not exist

Blogs

Cancer and Hair Loss
by Bob Riter
February 11, 2016